# Developing a Thermostable SARS-CoV-2 RBD-particle Vaccine

> **NIH NIH R43** · POP BIOTECHNOLOGIES, INC · 2022 · $299,991

## Abstract

PROJECT SUMMARY
The coronavirus disease 2019 (COVID-19) global pandemic caused by Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) is unprecedented in our lifetime and has caused major social, economic and
human suffering. Globally, there have been 76,858,506 confirmed cases, leading to 1,711,498 deaths as
reported by the WHO through December 2020. The rollout of FDA-authorized Pfizer (-80 ˚C storage) and
Moderna (-20 ˚C storage) vaccines has highlighted the challenges posed by low requisite storage temperatures.
Elimination of cold chain requirements for emerging vaccine solutions could facilitate distribution and provide
considerable supply chain cost savings. To overcome cold chain requirements, POP Biotechnologies proposes
to investigate a lyophilization strategy for its novel vaccine adjuvant platform that induces spontaneous antigen
particles, using the receptor-binding domain (RBD) of the SARS CoV-2 spike (S) protein. We were amongst the
first to show that a liquid form of RBD particles potently increases SARS-CoV-2 neutralizing antibodies by orders
of magnitude compared to the soluble antigen. Our vaccine platform induces the particle formation of well-
characterized his-tagged antigens by simple admixing with liposomes that contain small amounts of cobalt
porphyrin-phospholipid (CoPoP) and the clinical adjuvants monophosphoryl lipid A and QS-21. CoPoP
liposomes give rise to rapid antigen particleization that is stable in biological media. In this collaborative Phase I
SBIR proposal, we will assess the impact of lyophilization on the conformational and thermal stability of the
resulting lyophilized vaccine, evaluated by biochemical and biophysical assays, and its efficacy will be assessed
by functional immunogenicity in mice. This project will assess the feasibility of breaking the cold-chain
requirements for a next-generation particle vaccine system, which could be critical for resource-limited settings.
In collaboration with the Texas Biomedical Research Institute (TBRI), a transgenic mouse model for SARS-CoV-
2 infection will be used to study the thermostability on protection induced by the lyophilized, RBD particle vaccine.
1

## Key facts

- **NIH application ID:** 10448469
- **Project number:** 5R43AI165089-02
- **Recipient organization:** POP BIOTECHNOLOGIES, INC
- **Principal Investigator:** Wei-chiao Huang
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $299,991
- **Award type:** 5
- **Project period:** 2021-07-09 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10448469

## Citation

> US National Institutes of Health, RePORTER application 10448469, Developing a Thermostable SARS-CoV-2 RBD-particle Vaccine (5R43AI165089-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10448469. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*